Chemokines

CXCR7 modulator 1 (compound 25) is a potent and orally bioavailable peptoid hybrid CXCR7 modulator, with a K i of 9 nMForm:SolidIC50&amp Target:CXCR7 9 nM (Ki)

CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 ( CXCR7 ), with a K i of 13 nM.In VitroCXCR7 modulator 2 (compound 18) demonstrates potent CXCR7-binding affinity (K i =13 nM) and β-arrestin activity (EC 50 =11 nM). CXCR7

CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 ( CXCR7 ), with a K i of 13 nM.In VitroCXCR7 modulator 2 (compound 18) demonstrates potent CXCR7-binding affinity (K i =13 nM) and β-arrestin activity (EC 50 =11 nM). CXCR7

CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 ( CXCR7 ), with a K i of 13 nM.In VitroCXCR7 modulator 2 (compound 18) demonstrates potent CXCR7-binding affinity (K i =13 nM) and β-arrestin activity (EC 50 =11 nM). CXCR7

CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 ( CXCR7 ), with a K i of 13 nM.In VitroCXCR7 modulator 2 (compound 18) demonstrates potent CXCR7-binding affinity (K i =13 nM) and β-arrestin activity (EC 50 =11 nM). CXCR7

CXCR7 modulator 2 is a modulator of C-X-C Chemokine Receptor Type 7 ( CXCR7 ), with a K i of 13 nM.In VitroCXCR7 modulator 2 (compound 18) demonstrates potent CXCR7-binding affinity (K i =13 nM) and β-arrestin activity (EC 50 =11 nM). CXCR7

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation ( IC 50 of 260.7 nM) and shape